WHO is sponsoring a trial of two existing therapeutics for Bundibugyo Ebola: remdesivir, an antiviral, and MBP134, a monoclonal antibody cocktail (engineered proteins that bind and neutralise the virus) from Mapp Biopharmaceutical that is active across Ebola species1. In animal studies MBP134 gave 100% protection even when given up to eight days after infection2. The trial has not begun dosing; it awaits regulatory approval from the DRC and Ugandan governments3. This trial is the concrete answer to the gap flagged when the emergency was declared, when WHO confirmed no licensed countermeasure exists for this species and its R&D Blueprint had already named the Bundibugyo therapeutic gap.
National regulators in the DRC and Uganda must clear an investigational protocol, secure informed consent and stand up trial sites before any patient is dosed, and those are exactly the functions that conflict and a torched clinic erode. A trial needs a stable site, a traceable cohort and a chain of custody for samples; the South Kivu crossing and the 21% tracing ceiling in Ituri make all three harder to guarantee. The therapeutic that could cut the fatality rate is gated behind administrative steps that the outbreak's geography is actively dismantling.
No Bundibugyo-specific vaccine has reached even Phase 1. A ChAdOx-platform candidate is two to three months from producing trial doses but lacks safety data; an rVSV-platform candidate is six to nine months out45. ChAdOx and rVSV are the two viral-vector designs behind the Oxford COVID and licensed Zaire-Ebola vaccines. Roughly 2,000 doses of Ervebo, licensed only for Zaire ebolavirus, already sit in the DRC, and GAVI says they could be used in a trial if WHO experts judge it worth testing against a different species6. Every route to a vaccine here is measured in months, not days.
